-
Je něco špatně v tomto záznamu ?
Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response
T. Kropáčková, H. Mann, O. Růžičková, O. Šléglová, L. Vernerová, V. Horváthová, M. Tomčík, K. Pavelka, J. Vencovský, L. Šenolt
Jazyk angličtina Země Velká Británie
Typ dokumentu klinické zkoušky, srovnávací studie, časopisecké články, práce podpořená grantem
Free Medical Journals od 2011
Nature Open Access od 2011-12-01
PubMed Central od 2011
Europe PubMed Central od 2011
ProQuest Central od 2011-01-01
Open Access Digital Library od 2011-01-01
Open Access Digital Library od 2011-01-01
Health & Medicine (ProQuest) od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources od 2011
Odkazy
PubMed
34075162
DOI
10.1038/s41598-021-90973-2
Knihovny.cz E-zdroje
- MeSH
- biologické markery krev MeSH
- dospělí MeSH
- klusterin krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- revmatoidní artritida krev terapie MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
Clusterin (CLU) is a molecular chaperone that participates in a variety of biological processes. Recent studies indicate its possible involvement in the development of bone erosions and autoimmunity. The aim of this study was to investigate its serum concentrations in patients with early rheumatoid arthritis (RA) and to explore their potential relationship with disease activity and treatment response. Serum levels of CLU were measured in 52 patients before and 3 months after the initiation of treatment and in 52 healthy individuals. CLU levels at baseline were significantly increased in patients with early RA compared with healthy subjects (p < 0.0001). After 3 months of treatment, the levels of CLU decreased and reached concentrations comparable to those in controls. Even though there was no relationship between CLU levels and disease activity at baseline, CLU levels positively correlated with disease activity at months 3, 6 and 12 after treatment initiation. Using ROC analysis, lower CLU baseline levels predicted achieving the therapeutic target of low disease activity and remission at months 3, 6 and 12. In summary, we found increased serum concentrations of clusterin in treatment-naïve patients with early rheumatoid arthritis, and we suggest clusterin as a predictive biomarker of disease activity and treatment response.
Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic
Faculty of Science Charles University Prague Czech Republic
Institute of Rheumatology Na Slupi 4 128 00 Prague 2 Czech Republic
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22004296
- 003
- CZ-PrNML
- 005
- 20220127145353.0
- 007
- ta
- 008
- 220113s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-021-90973-2 $2 doi
- 035 __
- $a (PubMed)34075162
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kropáčková, Tereza $u Institute of Rheumatology, Na Slupi 4, 128 00, Prague 2, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- 245 10
- $a Clusterin serum levels are elevated in patients with early rheumatoid arthritis and predict disease activity and treatment response / $c T. Kropáčková, H. Mann, O. Růžičková, O. Šléglová, L. Vernerová, V. Horváthová, M. Tomčík, K. Pavelka, J. Vencovský, L. Šenolt
- 520 9_
- $a Clusterin (CLU) is a molecular chaperone that participates in a variety of biological processes. Recent studies indicate its possible involvement in the development of bone erosions and autoimmunity. The aim of this study was to investigate its serum concentrations in patients with early rheumatoid arthritis (RA) and to explore their potential relationship with disease activity and treatment response. Serum levels of CLU were measured in 52 patients before and 3 months after the initiation of treatment and in 52 healthy individuals. CLU levels at baseline were significantly increased in patients with early RA compared with healthy subjects (p < 0.0001). After 3 months of treatment, the levels of CLU decreased and reached concentrations comparable to those in controls. Even though there was no relationship between CLU levels and disease activity at baseline, CLU levels positively correlated with disease activity at months 3, 6 and 12 after treatment initiation. Using ROC analysis, lower CLU baseline levels predicted achieving the therapeutic target of low disease activity and remission at months 3, 6 and 12. In summary, we found increased serum concentrations of clusterin in treatment-naïve patients with early rheumatoid arthritis, and we suggest clusterin as a predictive biomarker of disease activity and treatment response.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a revmatoidní artritida $x krev $x terapie $7 D001172
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a klusterin $x krev $7 D051152
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mann, Heřman $u Institute of Rheumatology, Na Slupi 4, 128 00, Prague 2, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Růžičková, Olga $u Institute of Rheumatology, Na Slupi 4, 128 00, Prague 2, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Šléglová, Olga $u Institute of Rheumatology, Na Slupi 4, 128 00, Prague 2, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Vernerová, Lucia $u Institute of Rheumatology, Na Slupi 4, 128 00, Prague 2, Czech Republic
- 700 1_
- $a Horváthová, Veronika $u Institute of Rheumatology, Na Slupi 4, 128 00, Prague 2, Czech Republic $u Faculty of Science, Charles University, Prague, Czech Republic
- 700 1_
- $a Tomčík, Michal $u Institute of Rheumatology, Na Slupi 4, 128 00, Prague 2, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Pavelka, Karel $u Institute of Rheumatology, Na Slupi 4, 128 00, Prague 2, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Vencovský, Jiří $u Institute of Rheumatology, Na Slupi 4, 128 00, Prague 2, Czech Republic $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Šenolt, Ladislav $u Institute of Rheumatology, Na Slupi 4, 128 00, Prague 2, Czech Republic. senolt@revma.cz $u Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. senolt@revma.cz
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 11, č. 1 (2021), s. 11525
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34075162 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127145349 $b ABA008
- 999 __
- $a ok $b bmc $g 1751689 $s 1155445
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 11 $c 1 $d 11525 $e 20210601 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- LZP __
- $a Pubmed-20220113